hVIVO welcomed Matthew Blow as a new employee.

hVIVO plc (Ticker: HVO) is a science‑led early‑phase drug development company purpose‑built to meet the growing complexity of modern clinical research. The Company operates an integrated early‑phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‑ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials. With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise. The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.